Q-omics provides the consensus-scored RAB6B profile across patient tissues and cancer cell-line models. RAB6B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB6B is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, RAB6B RNA expression shows 24,023 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where RAB6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB6B survival associations across molecular data types. RAB6B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB6B RNA expression–survival associations across cancer types. High RAB6B expression shows unfavorable associations in KIRC, BLCA, UCEC and CESC, but favorable associations in LGG and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB6B RNA expression.
This table summarizes RAB6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB6B shows lower tumor expression in COAD, THCA and STAD and higher tumor expression in KIRP, LIHC and HNSC. The COAD box plot shows higher RAB6B RNA expression in normal versus tumor tissue (log2 FC = −1.279, t-test p < 0.001).
This table shows molecular features associated with RAB6B in patient tissues and cancer cell lines. In patient samples, RAB6B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
